<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02661009</url>
  </required_header>
  <id_info>
    <org_study_id>EGFR2015-01</org_study_id>
    <nct_id>NCT02661009</nct_id>
  </id_info>
  <brief_title>Human EGFR Mutations Quantitative Detection Kit (Real-time Fluorescent PCR Method)</brief_title>
  <official_title>Human EGFR(Epidermal Growth Factor Receptor) Mutations Quantitative Detection Kit (Real-time Fluorescent PCR Method)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GenoSaber</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Pulmonary Hospital, Shanghai, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GenoSaber</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this clinical trial, investigators select FFPE and plasma samples of non-small cell lung&#xD;
      cancer which are used for quantitative detection of four kinds of EGFR(Epidermal Growth&#xD;
      Factor Receptor) mutations. By the following two aspects, investigators evaluate the clinical&#xD;
      performance of the EGFR quantitative kits.&#xD;
&#xD;
        1. methodology validation: To certify the equivalence between the EGFR quantitative kit and&#xD;
           the common used detection methods.&#xD;
&#xD;
        2. analysis of the relationship between the type and proportion of EGFR sensitive mutation&#xD;
           and EGFR-TKI benefit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to the types of samples and the purpose of the study, the research consists of two&#xD;
      groups: plasma and tissue matching group and predicting clinical efficacy group. The samples&#xD;
      of the plasma and tissue matching group are the same period plasma and matched&#xD;
      FFPE(formalin-fixed paraffin-embedded tissue)samples which will be collected before the first&#xD;
      time patients accept any anti-tumor treatment. The samples of predicting clinical efficacy&#xD;
      group are FFPE samples which will be collected before the patients receive EGFR-TKI&#xD;
      treatment. In addition, the subjects have the complete prognostic follow-up data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2016</start_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>EGFR mutation detection of FFPE and plasma samples by Human EGFR Mutations Quantitative Detection Kit</measure>
    <time_frame>6 months</time_frame>
    <description>Each subject will be collected 3-10 FFPE samples and 3 ml plasma samples.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>EGFR-TKI Resistant Mutation</condition>
  <condition>EGFR-TKI Sensitizing Mutation</condition>
  <arm_group>
    <arm_group_label>Plasma and tissue matching</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>predicting clinical efficacy</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Non Small Cell Lung Cancer(stage Ⅲ-Ⅳ)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Plasma and tissue matching group:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  18~80 years old&#xD;
&#xD;
          -  Diagnosis of NSCLC (stage III or IV) which is confirmed by histology or cytology&#xD;
             methods.&#xD;
&#xD;
          -  Did not receive any anti-tumor treatment.&#xD;
&#xD;
          -  Sufficient samples for analysis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female patients of childbearing potential who are nursing or are pregnant.&#xD;
&#xD;
          -  Samples are collected after patients receiving anti-tumor treatment.&#xD;
&#xD;
          -  The plasma sample hemolysis.&#xD;
&#xD;
          -  Tumor cells are not found in FFPE samples.&#xD;
&#xD;
          -  Incomplete information of subjects&#xD;
&#xD;
        predicting clinical efficacy group:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  18~80 years old&#xD;
&#xD;
          -  Diagnosis of NSCLC (stage III or IV) which is confirmed by histology or cytology&#xD;
             methods.&#xD;
&#xD;
          -  At least one measurable focus&#xD;
&#xD;
          -  With EGFR-TKI treatment&#xD;
&#xD;
          -  Complete follow-up information after EGFR-TKI treatment&#xD;
&#xD;
          -  Sufficient samples for analysis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  FFPE samples are collected after EGFR-TKI treatment.&#xD;
&#xD;
          -  Female patients of childbearing potential who are nursing or are pregnant.&#xD;
&#xD;
          -  Tumor cells are not found in FFPE samples.&#xD;
&#xD;
          -  Incomplete information of subjects&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>January 18, 2016</study_first_submitted>
  <study_first_submitted_qc>January 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2016</study_first_posted>
  <last_update_submitted>January 20, 2016</last_update_submitted>
  <last_update_submitted_qc>January 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>EGFR</keyword>
  <keyword>EGFR-TKI</keyword>
  <keyword>PCR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

